Kyntra Bio Inc

Financials

Flusso di cassa derivante dalle attività operative -30.47 M2.72 M12.68 M-1.85 M-18.33 M -4.77 M Flussi di cassa derivanti dalle attività di investimento 1.72 M-16 K-13 K87.16 M-51.71 M 35.42 M Liquidità derivante dalle attività di finanziamento 5 000-88 K-9 000-85.92 M-14 K -86.03 M Liquidità libera -30.61 M2.7 M12.67 M-1.86 M-18.33 M -4.81 M

Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate. On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB.